Savient Pharmaceuticals (SVNT) Misses All Q1 Expectations

Savient Pharmaceuticals (NASDAQ: SVNT) reported Q1 EPS of ($0.49), $0.03 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $4.59 million.

For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c